<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572077</url>
  </required_header>
  <id_info>
    <org_study_id>2010539-01H</org_study_id>
    <nct_id>NCT01572077</nct_id>
  </id_info>
  <brief_title>Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension</brief_title>
  <acronym>RVMET</acronym>
  <official_title>Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate patterns of metabolic activity in the heart of&#xD;
      patients with pulmonary arterial hypertension(PAH). Patients with PAH are at risk of&#xD;
      developing weakness or failure of the right side of the heart.It is possible that there is a&#xD;
      relationship between the development of heart failure and the way the heart uses energy&#xD;
      sources, such as sugar. This study is designed to evaluate the way the heart uses sugar&#xD;
      uptake in patients with PAH using positron emission tomography(PET imaging)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAH results in premature death as a result of right ventricular dysfunction. However, there&#xD;
      are substantial differences among patients in their tendency to develop right heart failure.&#xD;
      This study proposes to determine if right ventricular (RV) changes can predict the&#xD;
      development of right heart failure in patients with PAH.&#xD;
&#xD;
      In addition, the study aims to evaluate the relationship of right ventricular metabolism to&#xD;
      other physiologic responses in PAH,including:pulmonary vascular resistance, serum BNP and&#xD;
      changes in cardiac hypertrophy and function. In conjunction with hemodynamic measurements,&#xD;
      biomarkers and cardiac magnetic resonance imaging (MRI); RV metabolism will be evaluated with&#xD;
      (18F) FTHA and (18F)FDG cardiac PET imaging.&#xD;
&#xD;
      A cohort of 20 age sex matched individuals will serve as normal controls. These subjects will&#xD;
      have no known cardiac or pulmonary disease with normal ventricular function and estimates&#xD;
      pulmonary pressures on echocardiogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiopulmonary death OR clinical right heart failure hospitalization</measure>
    <time_frame>1year</time_frame>
    <description>Clinical RHF admission requiring ONE of the following:intravenous diuretics or an increase in oral diuretics &gt;50%of baseline for at least 7 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in right ventricular size and function as measured by cardiac MRI, between baseline and 1 year.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>FTHA/GDF PET imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.&#xD;
Both groups will undergo FTHA/FDG PET imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FTHA, FDG PET imaging.</intervention_name>
    <description>Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).</description>
    <arm_group_label>FTHA/GDF PET imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:(PATIENTS)&#xD;
&#xD;
          -  Patients with diagnosis of Category 1 pulmonary arterial hypertension due to any of&#xD;
             the following: idiopathic, familial, associated with connective tissue disease, HIV&#xD;
             disease or anorexigen use.&#xD;
&#xD;
          -  All patients who will require a right heart catheterization for further clinical&#xD;
             management and/or diagnosis.&#xD;
&#xD;
          -  Patients will be considered eligible if they have no significant coronary artery&#xD;
             disease (stenosis &gt; 70% in a proximal or mid major coronary artery) or moderate&#xD;
             coronary artery disease (60-70%) with abnormal left ventricular function (EF&lt;50%)&#xD;
&#xD;
          -  Patients will be considered eligible in the absence of current or recent evidence of&#xD;
             right heart failure.&#xD;
&#xD;
          -  No previous hospital admission or requirements of intravenous diuretics for right&#xD;
             heart failure within 6 months of enrolment.&#xD;
&#xD;
          -  No increase in oral diuretics to control fluid volume within 6 months prior to&#xD;
             enrolment&#xD;
&#xD;
          -  No current symptoms and signs of fluid retention or right heart strain, including any&#xD;
             of the following: development of new ascites or peripheral edema &gt; = 2+, JVP &gt;7 cm&#xD;
             above the sternal angle or a right atrial pressure &gt;14 mmHg at the time of right heart&#xD;
             catheterization.&#xD;
&#xD;
          -  In addition, we will include a small cohort of up to 15 patients with PAH and current&#xD;
             RHF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known significant coronary artery disease(defined as known stenosis &gt;70%&#xD;
             in a proximal or mid major artery or moderate coronary artery disease (60-70%)in a&#xD;
             coronary artery and associated left ventricular ejection fraction &lt;50%.&#xD;
&#xD;
          -  Patients with diabetes mellitus who require the use of oral hypoglycemics and or&#xD;
             insulin.&#xD;
&#xD;
          -  Implantable metal devices, incompatible with magnetic resonance imaging.&#xD;
&#xD;
          -  Other contraindications of magnetic resonance imaging.&#xD;
&#xD;
        Normal Control Subjects:&#xD;
&#xD;
          -  Subjects will have no known cardiac or pulmonary disease.&#xD;
&#xD;
          -  Normal ventricular function and estimated pulmonary pressures on echocardiogram.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa M Mielniczuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Heart Institiute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of OttawaHeart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>April 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2012</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>Lisa Mielniczuk</investigator_full_name>
    <investigator_title>Co- Medical Director Pulmonary Hypertension Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

